Plain-English translation of NCT07100171 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing GM101, a new gene therapy injection designed to treat Parkinson's disease. The medication uses a specially modified virus to deliver genetic instructions into the brain, where it reprograms certain brain cells (called astrocytes) to become dopamine-producing neurons. This approach aims to restore the brain's natural ability to produce dopamine, the chemical messenger that Parkinson's disease disrupts.
People with advanced Parkinson's disease often find that standard medications stop working well or cause unbearable side effects. This trial exists because the treatment may offer hope for patients whose symptoms can no longer be adequately controlled by pills and injections alone.
You likely qualify if…
You likely don't qualify if…
You would undergo a surgical procedure to receive an injection of the medication directly into a specific brain region called the putamen. This is a one-time procedure performed under general anesthesia. After the injection, you would have regular follow-up visits over several months to monitor how your Parkinson's symptoms respond and check for any side effects. You would also keep a detailed diary of your symptoms and how you're functioning at home.
AI-generated summary from trial data · Jul 16, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Genemagic Biosciences Co., Ltd
Enrollment target
~10 participants
Started
May 2025
Primary completion
February 2027
Age range
40 Years – 70 Years
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Kaikai Li, Master
Genemagic Biosciences Co., Ltd
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.